Danapha
PHARMACEUTICAL JSC

Form B 01 - DN
(Issued pursuant to Circular No. 99/2025/TT-BTC dated October 27, 2025 of the Minister of Finance)

STATEMENT OF FINANCIAL POSITION

At 30/06/2026

Unit : VND

ASSET	Codes	Notes	As at 30 June.2026	As at 01 Jan.2026
A – CURRENT ASSETS	**100**		**533,390,169,415**	**657,862,535,833**
I. Cash and cash equivalents	**110**	V.01	**61,543,873,956**	**68,991,415,929**
1. Cash	111		7,126,041,548	68,991,415,929
2. Cash equivalents	112		54,417,832,408	
II. Short-term financial investments	**120**			
1. Trading securities	121			
2. Provision for decrease in value of trading securities (*)	122			
3. Investments held to maturity	123			
4. Provision for short-term investments held until maturity (*)	124			
5. Other short-term investments	125			
6. Provision for losses on other short-term investments (*)	126			
III. Short-term receivables	**130**		**281,461,247,310**	**432,752,858,144**
1. Short-term trade receivables	131	V.03	245,077,342,185	383,006,079,436
2. Short-term advance to suppliers	132	V.04	50,077,151,262	59,307,731,730
3. Short-term Inter-company receivables	133			
4. Payments due according to the construction contract schedule	134			
5. Other short-term receivables	135	V.05	7,276,550,225	6,379,279,372
6. Provision for doubtful short-term debts	136		(20,969,796,362)	(15,940,232,394)
7. Shortage of assets awaiting resolution	137	V.06		
IV. Inventories	**140**	V.07	**167,633,580,793**	**129,759,756,781**
1. Inventories	141		171,504,056,981	134,948,701,888
2. Provision for obsolete inventories (*)	142		(3,870,476,188)	(5,188,945,107)
V. Short-term biological assets	**150**			
1. Livestock raised for short-term, one-time production.	151			
2. Crops grown seasonally or for short-term, single-harvest production.	152			
3. Provision for short-term losses of biological assets (*)	153			
V. Other current assets	**160**		**22,751,467,356**	**26,358,504,979**
1. Short-term deferred expenses	161	V.11a	4,771,924,639	2,321,643,660
2. VAT deductibles	162		17,970,413,836	24,036,861,319
3. Tax and other receivables from State	163		9,128,881	
4. Buying-selling government's bonds transaction	164			
5. Other current assets	165			
B – NON-CURRENT ASSETS	**200**		**1,580,596,592,268**	**1,523,136,621,640**
I. Long-term receivables	**210**			
1. Long-term trade receivables	211			
2. Long-term advance to suppliers	212			
3. Paid-in capital in wholly owned subsidiaries	213			
4. Long-term inter-company receivables	214			
5. Other long-term receivables	215			
6. Provision for doubtful long-term receivables (*)	216			
II. Fixed assets	**220**		**811,345,623,659**	**95,705,685,342**
1. Tangible assets	221	V.09	776,564,474,683	60,459,260,810
- Cost	222		1,110,257,488,352	375,127,961,896
- Accumulated depreciation	223		(333,693,013,669)	(314,668,701,086)
2. Finance leases	224			
- Cost	225			
- Accumulated depreciation	226			
3. Intangible fixed assets	227	V.10	34,781,148,976	35,246,424,532

ASSET	Codes	Notes	As at 30 June.2026	As at 01 Jan.2026
- Cost	228		48,689,386,013	48,689,386,013
- Accumulated amortization	229		(13,908,237,037)	(13,442,961,481)
III. Long-term biological assets	**230**			
1. Regularly raise livestock for product production.	231			
a) Livestock raised for periodic production that have not yet reached maturity	232			
b) Livestock raised for regular production until they reach maturity	233			
- Cost	234			
- Accumulated amortization	235			
2. Livestock raised for a single, long-term product	236			
3. Crops grown seasonally or for long-term, single-product harvesting	237			
4. Provision for long-term losses of biological assets (*)	238			
IV. Investment properties	**240**			
- Cost	241			
- Accumulated depreciation	242			
V. Long-term assets in progress	**250**	V.08	**747,210,842,355**	**1,405,425,618,051**
1. Cost of long-term work in progress	251	V.08a		
2. Construction in progress	252	V.08b	747,210,842,355	1,405,425,618,051
VI. Long-term financial investments	**260**	V.02	**6,800,000,000**	**6,800,000,000**
1. Investments in subsidiaries	261			
2. Investments in joint ventures and associates	262		8,820,000,000	8,820,000,000
3. Equity investments in other entities	263		6,800,000,000	6,800,000,000
4. Provision for long-term investment losses in other entities (*)	264		(8,820,000,000)	(8,820,000,000)
5. Long-term investment holding until maturity	265			
6. Provision for long-term investments held to maturity (*)	266			
VII. Other long-term assets	**270**		**15,240,126,254**	**15,205,318,247**
1. Long-term deferred costs	271		15,240,126,254	15,205,318,247
2. Deferred tax assets	272			
3. Long-term equipment, supplies and spare parts	273			
4. Other long-term assets	274			
TOTAL ASSETS (280 = 100 + 200)	**280**		**2,113,986,761,683**	**2,180,999,157,473**
C. LIABILITIES	**300**		**1,192,620,240,971**	**1,330,322,211,589**
I. Current liabilities	**310**		**682,172,177,948**	**516,317,754,059**
1. Short-term trade payables	311	V.13a	183,540,663,029	199,879,488,319
2. Short-term advance from customers	312		7,701,871,028	1,906,820,492
3. Dividends and profits must be paid.	313		10,090,920	
4. Tax and statutory obligations	314	V.14	25,653,925,211	16,607,966,690
5. Payables to employees	315		23,124,594,413	32,408,028,038
6. Short-term accruals	316	V.15	26,021,365,620	34,535,784,509
7. Short-term inter-company payables	317			
8. Payment must be made according to the progress of the short-term construction contract.	318			
9. Short-term deferred revenue	319			
10. Other short-term payables	320	V.16	11,683,637,894	32,761,761,777
11. Short-term loans and finance lease liabilities	321	V.12a	403,128,466,260	196,846,881,622
12. Preventive for short-term payables	322			
13. Bonus and welfare funds	323		1,307,563,573	1,371,022,612
14. Price stabilization fund	324			
15. Buying-selling government's bonds transaction	325			
II. Non-current liabilities	**330**		**510,448,063,023**	**814,004,457,530**
1. Long-term trade payables	331	V.13b	217,784,327,145	328,383,111,022
2. Long-term advance from customers	332			
3. Taxes and other long-term payments to the State.	333			
4. Long-term accruals	334			
5. Inter-company payables on working capital	335			
6. Long-term inter-company payables	336			

ASSET	Codes	Notes	As at 30 June.2026	As at 01 Jan.2026
7. Revenue awaiting long-term allocation	337			
8. Other long-term liabilities	338			
9. Long-term loans and finance lease liabilities	339	V.12b	292,417,136,083	480,985,536,083
10. Convertible bonds	340			
11. Preference shares	341			
12. Deferred tax liabilities	342		246,599,795	4,635,810,425
13. Preventive for long-term payables	343			
14. Development of sciene and technology fund	344			
D. OWNERS' EQUITY	**400**		**921,366,520,712**	**850,676,945,884**
1. Owner's contributed capital	411	V.17a	209,380,000,000	209,380,000,000
- Ordinary shares with voting rights	411a		209,380,000,000	209,380,000,000
- Preference shares	411b			
2. Share prenium	412		181,169,607,584	181,169,607,584
3. Conversion options on bond	413			
4. Other owners' capital	414			
5. Shares repurchased from oneself (*)	415			
6. Asset revaluation reserve	416			
7. Foreign exchange differences	417			
8. Investment and development fund	418	V.17b	460,127,338,300	374,134,185,572
9. Other funds belonging to owner's equity	419			
10. Undistributed profit after tax	420		70,689,574,828	85,993,152,728
- Undistributed profit after tax of previous period	420a			243,600,000
- Undistributed profit after tax of current period	420b		70,689,574,828	85,749,552,728
TOTAL RESOURCES (440 = 300+ 400)	**440**		**2,113,986,761,683**	**2,180,999,157,473**

Approve, July 18th 2026

PREPARER	**CHIEF ACCOUNTANT**	**LEGAL REPRESENTATIVE**
(Signature, full name)	(Signature, full name)	(Signature, full name, seal)
Nguyen Thi Thu Hang	**Tran Tien Dung**	**PhD. Le Thang Binh**

Danapha PHARMACEUTICAL JSC

Form B 02 - DN

(Issued pursuant to Circular No. 99/2025/TT-BTC dated October 27, 2025 of the Minister of Finance)

INCOME STATEMENT

Quarter 2.2026

Unit: vnd

ITEMS	Codes	Notes	Quarter 2		Cumulative from the beginning of the year to the end of this quarter	
			Current year	Previous year	Current year	Previous year
1	2	3	4	5	6	7
1. Revenue from sale of goods and rendering of services	1	VI.01	193,342,607,128	155,396,958,947	329,028,284,223	295,997,578,093
2. Deductions	2	VI.02	1,947,656,505	358,014,417	2,575,781,083	1,378,070,622
3. Net revenue from sale of goods and rendering of services (10 = 01 - 02)	10		191,394,950,623	155,038,944,530	326,452,503,140	294,619,507,471
4. Cost of goods sold and services rendered	11	VI.03	90,525,116,479	70,320,305,276	146,181,271,161	133,278,850,454
5. Gross profit from sale of goods and rendering of services (20 = 10 - 11)	20		100,869,834,144	84,718,639,254	180,271,231,979	161,340,657,017
6. Profit/loss from the sale and liquidation of investment properties	21		-	-	-	-
7. Income form financial activities	22	VI.04	1,698,328,677	3,215,640,003	18,262,909,299	3,749,071,061
8. Expenses from financial activities	23	VI.05	5,587,573,709	24,328,250,596	10,151,397,802	32,263,428,528
- In which : Interest expenses	24		5,068,983,773	2,057,730,127	9,581,105,054	3,914,351,333
9. Selling expenses	25	VI.08	16,371,256,757	25,172,843,927	40,545,080,899	49,553,716,091
10. Adminitration expenses	26	VI.09	34,864,801,665	27,549,460,009	57,814,496,133	53,223,190,595
11. Operating profit (loss) {30 = 20 + (21 - 22) - (25 + 26)}	30		45,744,530,690	10,883,724,725	90,023,166,444	30,049,392,864
12. Other income	31	VI.06	319,221,888	36,300,752	348,256,587	106,363,848
13. Other expenses	32	VI.07	153,549,816	59,197,781	163,566,816	67,791,615
14. Other profit (40 = 31 - 32)	40		165,672,072	(22,897,029)	184,689,771	38,572,233
15. Accounting profit (loss) before tax (50 = 30 + 40)	50		45,910,202,762	10,860,827,696	90,207,856,215	30,087,965,097
16. Current enterprise income tax expense	51		10,462,721,743	(1,254,508,741)	23,907,492,017	1,317,035,226
17. Deferred income tax (expenses) credit	52	VI.10	(1,488,277,305)	4,225,027,793	(4,389,210,630)	4,225,027,793
18. Net profit (loss) after tax (60 = 50 - 51 - 52)	60		36,935,758,324	7,890,308,644	70,689,574,828	24,545,902,078
19. Basic earnings per share (*)	70		-	-	0	0
20. Diluted earnings per share (*)	71		-	-	0	0

Approve, July 18th 2026

PREPARER	CHIEF ACCOUNTANT	LEGAL REPRESENTATIVE
(Signature, full name	(Signature, full name)	(Signature, full name, seal)
Nguyen Thi Thu Hang	Tran Tien Dung	PhD. Le Thang Binh

M.S.D.N: 0400102091 - C.T.C.P - CÔNG TY CỔ PHẦN DƯỢC DANAPHA - THÀNH PHỐ ĐÀ NẴNG

Danapha
PHARMACEUTICAL JSC

Form B 03 - DN
(Issued together with Circular No. 99/2025/TT-BTC dated October 27, 2025 of the Minister of Finance.)

CASH FLOW STATEMENT

(By indirect method)

Quarter 2.2026

Unit : vnd

ITEMS	Codes	Notes	Current period	Previous period
I. Cash flows from operating activities				
1. Net profit/(loss) before tax	**01**		**90,207,856,215**	**30,087,965,097**
2. Adjustments for				
- Depreciation and amortization	02		22,659,588,787	8,463,880,336
- Provisions	03		4,990,468,733	3,017,332,842
- Unrealised foreing exchange (gain) losses	04		11,554,826	(3,058,266)
- (Profit) losses from investing activities, financial activities	05		(276,859,539)	(650,433,261)
- Interest expense	06		9,581,105,054	3,914,351,333
3. Operating income (loss) before changes in working capital	**08**		**127,173,714,076**	**44,830,038,081**
- (Increase)/decrease in receivables	09		152,319,365,467	(81,402,155,685)
- (Increase)/decrease in inventories	10		(38,677,631,064)	(19,474,776,330)
- Increase/(decrease) in payables (exclusive of interest payable and enterprise income tax payable)	11		(57,769,998,163)	71,001,227,835
- (Increase)/decrease prepaid expenses	12		(2,485,088,985)	84,157,098
- (Increase)/decrease trading securities	13			
- Interest expenses paid	14		(5,849,183,468)	(3,813,370,620)
- Enterprise income tax paid	15		(18,381,066,861)	(23,595,305,924)
- Other cash inflows from operating activities	16			
- Other cash outflows from operating activities	17		(42,250,951,465)	(14,190,905,826)
Net cash inflows (outflows) from operating activities	**20**		**114,079,159,537**	**(26,561,091,371)**
II. Cash flows from investing activities				
Purchased and construction of fixed assets and other long-term assets	21		(139,557,623,269)	(121,209,829,777)
Proceeds from disposals of fixed assets and other long-term assets	22			
Loans to other entities and payments for purchase of debt instruments of other entities	23			
Collections from borrowers and proceeds from sale of debt instruments of other entities	24			
Payments for investment in other entities	25			
Proceeds from sale of investments in other entities	26			
Interest, distributed dividends and profit received	27		276,859,539	887,849,329
Net cash inflows (outflows) from investing activities	**30**		**(139,280,763,730)**	**(120,321,980,448)**

ITEMS	Codes	Notes	Current period	Previous period
III. Cash flows from financing activities				
Capital contribution and issuance of share	31			
Capital redemption	32			
Borrowings received	33		534,392,150,064	324,587,384,078
Borrowings repaid	34		(516,678,965,426)	(174,257,879,763)
Profit, dividents paid	36			
Net cash inflows (outflows) from financing activities	**40**		**17,713,184,638**	**150,329,504,315**
Net cash inflows (outflows) (50 = 20 + 30 + 40)	**50**		**(7,488,419,555)**	**3,446,432,496**
Cash and cash equivalents at the beginning of the year	60		68,991,415,929	74,551,503,101
Impact of exchange rate fluctuation	61		(11,554,826)	3,058,266
Cash and cash equivalents at end of the year (70 = 50 + 60 + 61)	**70**		**61,491,441,548**	**78,000,993,863**

Da Nang, July 18th, 2026

Preparer	Chief Accountant	General Director
(Signature, full name)	(Signature, full name)	(Signature, full name, seal)
Nguyen Thi Thu Hang	**Tran Tien Dung**	**PhD. Le Thang Binh**

NOTES TO THE FINANCIAL STATEMENTS

At June 30th 2026

I. CORPORATE INFORMATION

1. Structure of ownership Joint Stock Company

Danapha Pharmaceutical Joint Stock Company (hereinafter referred to as "the Company") has been incorporated in accordance with the Business Registration Certificate No. 0400102091 dated 20 December 2006 granted by Danang City's Department of Planning and Investment and other amended certificates thereafter with the latest one dated 16th December 2025.

The charter capital as stipulated in the Business Registration Certificate is VND 209,380,000,000.

On 14 December 2021, the Company was formally licensed to trade securities on Hanoi Securities Trading Centre under Decision No. 703/QĐ-SGDHN dated 14 December 2021. On 22 December 2021, the Company was formally listed to trade securities on Hanoi City Securities Trading Centre according to the Notification No. 3654/TB-SGDHN dated 15 December 2021.

The Company's registered head office is at 253 Dung Si Thanh Khe Street, Thanh Khe Ward, Da Nang City, Vietnam.
The company has branches at the following locations:
Hanoi Branch: No. 9, Alley 87 Nguyen Van Troi, Thanh Xuan Ward, , Hanoi City.
Ho Chi Minh City Branch: 15th Floor, Room 1508, Vincom Center Building, 72 Le Thanh Ton Street, Sai Gon Ward, Ho Chi Minh City.
Thanh Hoa Branch: Lot 141, LK3, MBQH 121/UB-CN, Hac Thanh Ward , Thanh Hoa Province, Vietnam.
Khanh Hoa Branch: Lots 27-28, Street No. 8, Le Hong Phong New Urban Area - Venesia, Nam Nha Trang Ward, Khanh Hoa.
Vinh Phuc Branch: No. 43, Chua Ha Tien Urban Area, Vinh Phuc Ward, Phu Tho District.
Can Tho Branch: A3/22, Street No. 10, Nam Long Residential Area, Cai Rang Ward, Can Tho City.

2. Operating industry and principal activities

- Manufacture of pharmaceuticals, medicinal chemical and botanical product;
- Real estate activities with own or leased property;
- Retail sale of pharmaceutical and medical goods, cosmetic and toilet articles in specialized stores. Details: Retail sale of pharmaceutical and medical goods, cosmetics, and personal hygiene products;
- Manufacture of soap and detergents, cleaning and polishing preparations;
- Manufacture of other food products n.e.c. Details: Production of food and beverages;
- Wholesale of other household products. Details: Wholesale of medicines;
- Wholesale of food. Details: Wholesale of dietary supplements;
- Wholesale of other specialized goods not classified elsewhere. Details: Wholesale of pharmaceuticals, medicinal plants, packaging;
- Retail sales via mail and order houses or via Internet. Details: Retail of dietary supplements;
- Retail of food in specialized stores. Details: Retail of dietary supplements;
- Other professional, scientific, and technological activities not classified elsewhere. Details: Research and transfer of product formulas.
- Manufacture of medical, dental, orthopedic, and rehabilitation equipment and instruments.
- Basic training
- Intermediate training
- College-level training

3. Business field

Manufacturing and trading pharmaceutical, chemical, and medicinal materials.

4. Total number of employees and workers.

The number of employees as at June 30th 2026 was 521 person (including 06 probationary employees and 11 trainees).

II. ACCOUNTING PERIOD, ACCOUNTING CURRENCY APPLIED

1. Accounting period:

- Fiscal year starts on 01/01 and ends on 31/12 each year.

2. Accounting currency applied

- The standard currency unit used is Vietnamese Dong (VND).
- Transactions denominated in foreign currencies are translated into Vietnamese Dong at the average exchange rate applicable at the transaction date. Any exchange differences arising from such transactions are recognized as income or expenses in the Statement of Profit or Loss.

III. ACCOUNTING STANDARD AND POLICY APPLIED

1.Accounting policy applied

The Company has been applying the Vietnamese accounting system, issued following Decision No. 99/2025/TT-BTC dated October 27th, 2025 of the Ministry of Finance and related supplementary, revised documents.

2. Statement of compliance with Vietnamese accounting standards

- The Company has fully complied with the requirements of the current Vietnamese Accounting Standards and the Vietnamese Accounting Regime in the preparation and presentation of the Financial Statements.
- The Financial Statements present fairly and reasonably the financial position, results of operations, and cash flows of the Company.

IV. ACCOUNTING POLICIES APPLIED

1. Basis of Preparation of Financial Statements:

- The financial statements are prepared based on the historical cost principle.
- The company's branches operate under the bookkeeping reporting system.

2. Cash and cash equivalents

- Cash and cash equivalents comprise cash in hand, cash at bank, cash in transit and current investments for a period not exceeding 3 months or highly liquid investments which are readily convertible to known amounts of cash and which are subject to an insignificant risk of changes in value.

3. Inventories

Inventories are stated at the lower of cost and net realizable value
Cost of inventories is calculated follows:

• Materials: Cost comprises costs of purchase, costs of conversion and any directly attributable costs of bringing the inventories to their present location and condition.

• Cost of work in progress: only includes the cost of main materials and other expenses.

Net realizable value is the estimated selling price minus the estimated costs of completing the products and the estimated costs needed for their consumption.
Cost of inventories method: the weighted average method and is recorded by the perpetual inventory count method.
Provision method for obsolete inventories: Provision for obsolete inventories is set up when cost is higher than net realizable value at the end of the accounting period.
Increase or decrease in balance of the provision for obsolete inventories that need to be made at the end of the fiscal year is recognized in cost of goods sold.

4. Account receivables

- Recognition method:

Account receivables are stated at the carrying amounts of trade receivables and other receivables less provisions for doubtful debts.

- Provision for doubtful debts:

As of the date of preparing the financial statements, provision for doubtful debt is recognised for past-due accounts receivable and for accounts receivable where circumstances indicate that they might not be recoverable when due at the level as guided in prevailing regulations. The determination of the overdue period of a doubtful receivable to be provisioned is based on the principal repayment period according to the original sale contract, excluding the debt extension
The difference between the required balance and the existing balance of provision for doubtful debts is recorded as a general and administrative expense in the income statement.

5. Tangible fixed asset

- Tangible fixed assets are measured at cost less accumulated depreciation. Tangible fixed assets are initially recognised at their cost. The cost of purchased tangible fixed assets comprises the purchase price and any directly attributable costs of bringing the assets to their present location and working condition for their intended use. Accessories added to fixed assets when purchased are recognised separately at their fair value and deducted from the historical cost of the respective tangible fixed assets.
- When fixed assets are sold or disposed of, the original cost and accumulated depreciation are removed, and any profit or loss arising from the disposal is recognized as income or expense in the period
- The costs of fixed assets are depreciated on a straight-line method over their estimated useful lives.

The estimated useful lives are as follows:	Year
+ Buildings, structures	10 - 50
+ Machinery and equipment	06 - 15
+ Motor vehicles	06 - 10
+ Office equipment	03 - 08

6. Intangible fixed assets:

6.1. Intangible fixed assets of the company are software:

- Intangible fixed assets of the company are software. The historical cost of software includes all costs directly attributable to making software available for use. Accounting software is depreciated by straight – line method from 01 to 05 years.

6.2. Land Use Rights:

- "Long-term land use rights" refer to the total costs incurred by the company to acquire the right to use the land in order to generate economic benefits. The cost of long-term land use rights is not subject to depreciation as prescribed by law.

7. Construction in progress:

- Construction in progress reflects the related direct costs (including interest expense capitalized) until the asset is in the process of building, machinery and equipment are installed to serve for the purpose of manufacturing, leasing and management, as well as costs related to the repair of fixed assets are performing. These assets are recorded at cost and are not amortized.

8. Borrowing costs:

- Borrowing costs directly attributable to the acquisition, construction or production of qualifying assets, that necessarily take a substantial period of time to get ready for their intended use or sale, are capitalised as part of the cost of those assets until the assets are put into use or sale. Investment income earned on temporary investment of borrowings is deducted from the cost of the respective assets. All other borrowing costs are recognised as an expense in the consolidated income statement when incurred.

9. Financial investments:

- Investments classified as other investments are investments other than investments in subsidiaries, investments in associates or investments on joint ventures.
- Provision for investment impairment loss is made when there is any certain evidence that there will be an impairment in the value of these investments at the
- The difference between the required balance and the existing balance of provision for investment impairment loss is recognised as financial expenses in the

10. Prepayments:

- Prepayments are classified as current and non-current based on their original term. Prepayments mainly comprise costs of tools and supplies and repair expenses, etc., which are amortised over the period for which they are paid or the period in which economic benefits are generated in relation to these expenses.
- The following expenses are recognised as prepayments and amortised to the consolidated income statement:
+ Prepaid land, infrastructure and fixed asset rentals are amortised over the period of lease;
+ Other prepaid expenses: Based on the nature and volume of each expense, the company selects appropriate methods and criteria for allocation during the period when the expected economic benefits are generated.

11. Liabilities:

- Liabilities are classified into trade payables and other payables based on the following rules: Trade payables represent those arising from purchase and sale related transactions of goods, services or assets and the seller is independent of the buyer; the remaining payables are classified as other payables.

12. Accrued expenses:

- Accrued expenses represent expenses that will be paid in the future for goods or services received but not yet paid due to lack of invoices or accounting documents. These expenses are recognised as operating expenses of the reporting year.
- The company's accrued expenses include loan interest and sales commission expenses. Estimated loan interest expenses are calculated based on the outstanding loan balance and the interest rates specified in the credit agreements. Sales commission expenses are determined according to the sales policy applicable during each actual period.

13. Severance Allowance and Unemployment Insurance:

- The company allocates unemployment insurance expenses and directly deducts them from employees in accordance with current regulations.

14. Owners' equity:

- The owners' contributed equity is recognised when contributed.
- Share premiums are recognised as the difference between the issue price and the par value of shares, and the difference between the re-purchase price and the re-issue price of treasury shares.
- Retained earnings: Net profit after income tax can be distributed to shareholders after the distribution is approved the General annual meeting of shareholders and reserves are created in accordance with the Charter and legal regulations in Vietnam.

15. Revenue and other income:

Revenue from selling goods:

+ Revenue from selling goods is measured at the fair value of the consideration received or receivable. In most cases, revenue is recognised when transferring the risks and rewards of ownership to the buyer.

Revenue involving the rendering of services:

- Revenue of a transaction involving the rendering of services is recognised when the outcome of this transaction can be estimated reliably. When a transaction involving the rendering of services is attributable to several periods, each period's revenue is recognised by reference to the stage of completion at the end of the reporting period.

Principles and Methods for Recognizing Financial Incom:

- Financial income reflects revenue from interest, dividends, profit sharing, and other financial activities of the enterprise (such as investments in associates, other capital investments, foreign exchange gains, etc.). Revenue arising from interest, dividends, and profit sharing of the enterprise is recognized when the following two conditions are simultaneously met: 1. It is probable that economic benefits will be obtained from the transaction; 2. The revenue can be measured with reasonable certainty. - Interest is recognized on a time basis using the actual interest rate for each period. - Dividends and profit sharing are recognized when shareholders are entitled to receive dividends or when participants in the contribution are entitled to their share.

16. Finance expense:

- CFinance expenses represent all expenses incurred in the reporting year which mainly include borrowing costs and losses from exchange rates.

17. Corporate income tax:

- Current corporate income tax expense
- The current applicable corporate income tax (CIT) rate is 20% for manufacturing and business activities. In fiscal year 2026, the Company generated revenues but did not have any taxable income; therefore, this is considered the first year in which the preferential CIT rate of 10% is applied in accordance with the CIT incentive regulations.

18. Related parties:

- Related parties are individuals or entities that have the ability, directly or indirectly through one or more intermediaries, to control the Company or are controlled by, or are subject to common control with the Company. Associates, individuals owning, directly or indirectly, an interest in the voting power of the Company that gives them significant influence over the Company, key management personnel, including directors and officers of the Company and close family members or associates of such individuals are also considered to be related parties.

V. ADDITIONAL INFORMATION FOR ITEMS SHOWN IN THE BALANCE SHEET

Unit of measurement: VND

01. Cash and cash equivalents:

	Foreign currencies	At as 30/06/2026	Foreign currencies	At as 01/01/2026
- Cash in hand		372,078,900		356,169,155
+ VND		323,248,186		307,726,694
+ USD	1,857.67 #	48,830,714	1,857.67 #	48,442,461
- Cash at banks		6,753,962,648		68,635,246,774
+ VND		6,654,923,521		14,267,193,556
+ USD	939.37 #	24,675,604	612.86 #	15,950,240
+ EUR	2,464.36 #	74,363,523	1,790,921.47 #	54,352,102,978
- Deposits with term less than 3 months (EUR)	#	54,417,832,408		-
+ EUR	1,800,000	54,365,400,000		-
+ Accrued Interest Receivable		52,432,408		-
Totals		**61,543,873,956**		**68,991,415,929**

02. Current financial investments

Investment in other entities:

	At as 30/06/2026			At as 01/01/2026		
	Original cost	Recoverable value	Provision	Original cost	Recoverable	Provision
- Investments in subsidiaries	-	-	-	-	-	-
- Investments in associates, jointly	**8,820,000,000**	-	**8,820,000,000**	**8,820,000,000**	-	**8,820,000,000**
+ Davina Pharmaceutical Joint Stock Company	8,820,000,000	-	8,820,000,000	8,820,000,000	-	8,820,000,000
- Other long-term investments	6,800,000,000	6,800,000,000	-	**6,800,000,000**	6,800,000,000	-
+ Danang Pharmaceutical Medical Equipment Joint Stock Company (Dapharco)	6,800,000,000	6,800,000,000	-	6,800,000,000	6,800,000,000	-
Totals	**15,620,000,000**	**6,800,000,000**	**8,820,000,000**	**8,820,000,000**	**6,800,000,000**	**8,820,000,000**

03. Receivable from customer:

	At as 30/06/2026		At as 01/01/2026	
Short-term	**Book Value**	**Provision**	**Book Value**	**Provision**
- Danhson-BG Ood	105,186,767,429		245,319,144,115	
- Dong Thap Psychiatric Hospital	4,136,720,400		5,016,495,400	
- Kien Giang Psychiatric Hospital	3,370,007,500		549,696,500	
- FL Distribution, s.r.o	3,112,821,251		3,134,607,968	
- Other receivables	129,271,025,605	4,768,040,979	128,986,135,453	4,594,439,971
Totals	**245,077,342,185**	**4,768,040,979**	**383,006,079,436**	**4,594,439,971**

04. Short-term advance to suppliers

	At as 30/06/2026		At as 01/01/2026	
	Book Value	**Provision**	**Book Value**	**Provision**
- Joy – Maitreya International Ltd.	16,186,543,200	16,186,543,200	16,186,543,200	11,330,580,240
- Handaco Vietnam Co., Ltd.	2,589,000,000	-	3,297,000,000	-
- Lloyd Laboratories Inc.	2,242,969,076	-	-	-
- Rudolf Lietz, Inc (USD)	1,799,547,750	-	-	-
- Greensol Co., Ltd.	-	-	6,268,766,087	-
- Other receivables	27,259,091,236	-	33,555,422,443	-
Totals	**50,077,151,262**	**16,186,543,200**	**59,307,731,730**	**11,330,580,240**

05. Other receivables:

	At as 30/06/2026		At as 01/01/2026	
	Book Value	**Provision**	**Book Value**	**Provision**
- Short-term	7,276,550,225	15,212,183	6,379,279,372	15,212,183
Advance to employees	4,721,141,349	-	5,688,003,672	
Mortgage, guarantee deposit	228,836,195	-	310,536,525	
Accrued interest		-		
Other receivables	2,326,572,681	15,212,183	380,739,175	15,212,183
- Long-term	-	-	-	-
Mortgage, guarantee deposit	-	-	-	-
Totals	**7,276,550,225**	**15,212,183.00**	**6,379,279,372**	**15,212,183**

06. Assets pending resolution:

	At as 30/06/2026		At as 01/01/2026	
	Book Value	**Provision**	**Book Value**	**Provision**
- Other assets				
Totals				

07. Inventories:

	At as 30/06/2026		At as 01/01/2026	
	Book Value	**Recoverable value**	**Book Value**	**Recoverable value**
- Goods in transition	4,258,053,033		6,380,329,004	
- Raw materials	76,675,585,830	3,341,288,946	68,938,174,008	4,367,965,385
- Tools and supplies	300,951,311		318,139,156	
- Work in progress	11,856,744,150		15,725,654,311	
- Finished products	77,047,359,179	529,187,242	43,586,405,409	820,979,722
- Goods	1,365,363,478			
Totals	**171,504,056,981**	**3,870,476,188**	**134,948,701,888**	**5,188,945,107**

asset in progress:

	At as 30/06/2026		At as 01/01/2026	
	Original cost	Provision	Book Value	Provision
Cost of long-term work in progress				
Construction in progress				
Pharmaceutical OSD Production Plant and High-tech Research and Development Center	*638,064,147,696*	*638,064,147,696*	*1,312,500,531,193*	*1,312,500,531,193*
- Nguyen Van Linh Office Building for Rent	*107,785,903,364*	*107,785,903,364*	*91,579,319,637*	*91,579,319,637*
- Other projects	*1,360,791,295*	*1,360,791,295*	*1,345,767,221*	*1,345,767,221*
Totals	**747,210,842,355**	**747,210,842,355**	**1,405,425,618,051**	**1,405,425,618,051**

09. Tangible fixed assets:

Khoản mục	Buildings, and structures	Machines, and equipment	Means of transportation	Office equipment	Totals
HISTORICAL COST					
At as 01/01/2026	**144,571,793,790**	**215,239,263,528**	**15,316,904,578**	**-**	**375,127,961,896**
Purchase in year		586,288,519	633,001,345	-	1,219,289,864
XDCB hình thành	385,278,149,364	347,148,105,543	4,653,982,333	-	737,080,237,240
Chuyển sang BĐS Đầu tư				-	-
Liquidate, disposal		3,170,000,648		-	3,170,000,648
At as 30/06/2026	**144,571,793,790**	**212,655,551,399**	**15,949,905,923**	**-**	**1,110,257,488,352**
ACCUMULATED DEPRECIATION					
At as 01/01/2026	**108,244,843,891**	**194,997,622,289**	**11,426,234,906**	**-**	**314,668,701,086**
Depreciation in year	6,494,803,410	15,149,398,450	550,111,371	-	22,194,313,231
Liquidate, disposal		3,170,000,648		-	3,170,000,648
At as 30/06/2026	**114,739,647,301**	**206,977,020,091**	**11,976,346,277**		**333,693,013,669**
NET BOOK VALUE					
At as 01/01/2026	**36,326,949,899**	**20,241,641,239**	**3,890,669,672**	**-**	**60,459,260,810**
At as 30/06/2026	**29,832,146,489**	**5,678,531,308**	**3,973,559,646**	**-**	**776,564,474,683**

10. Intangible fixed assets:

Khoản mục	Land use rights	Mastheads and publishing titles	Softwares	Other intangible assests	Totals
HISTORICAL COST					
At as 01/01/2026	**48,689,386,013**	-	-	-	**48,689,386,013**
Mua mới	-	-	-	-	-
Giảm khác	-	-	-	-	-
At as 30/06/2026	**48,689,386,013**	-	-	-	**48,689,386,013**
ACCUMULATED DEPRECIATION					
At as 01/01/2026	**13,442,961,481**	-	-		**13,442,961,481**
Depreciation in year	465,275,556	-	-	-	465,275,556
At as 30/06/2026	**13,908,237,037**	-	-	-	**13,908,237,037**
NET BOOK VALUE					
At as 01/01/2026	**35,246,424,532**	-	-	-	**35,246,424,532**
At as 30/06/2026	**34,781,148,976**	-	-	-	**34,781,148,976**

11. Long-term deferred costs

	At as 30/06/2026	At as 01/01/2026
a. Short-term prepaid expenses	**4,771,924,638**	**2,321,643,660**
- Prepaid expenses on operating leases of fixed assets	1,670,772,873	125,787,991
- Tools and instruments are used	676,731,588	1,402,959,509
- Insurance costs	253,956,211	45,811,085
- Other service expenses	2,170,463,966	747,085,075
b. Long-term prepaid expenses	**15,240,126,254**	**15,205,318,247**
- Land rental fee	11,557,318,080	11,797,262,400
- Repair cost	-	-
- Other service expenses	3,682,808,174	3,408,055,847
Cộng	**20,012,050,892**	**17,526,961,907**

12. Loans and finance lease liabilities

	At as 30/06/2026	Additions	Reductions	At as 01/01/2026
a. Short-term loans	**403,128,466,260**	**471,766,650,064**	**265,485,065,426**	**196,846,881,622**
Foreign Trade of Vietnam - Da Nang Branch	-	-	44,736,044,389	44,736,044,389
- Vietnam Joint Stock Commercial Bank for Industry and Trade - Da Nang Branch	38,518,229,453	52,518,229,453	33,308,247,397	19,308,247,397
- Vietnam Technological and Commercial Joint Stock Bank - Da Nang Branch	18,011,361,372	40,231,437,943	43,161,328,712	20,941,252,141
- Vietnam Bank for Agriculture and Rural Development	96,893,078,336	135,770,585,569	138,762,244,928	99,884,737,695
- Danang City Development Investment Fund	17,645,800,000	11,186,400,000.00	5,517,200,000	11,976,600,000
- Joint Stock Commercial Bank for Investment and Development of Vietnam (BIDV)	6,317,497,099	6,317,497,099	-	-
- Danang City Development Investment Fund	225,742,500,000	225,742,500,000	-	-
b. Long-term loans	**292,417,136,083**	**60,353,000,000**	**248,921,400,000**	**480,985,536,083**
Long-term foreign currency loan (EUR)		-	*237,735,000,000*	*237,735,000,000*
- Danhson - BG Ltd (EUR)*	-	-	237,735,000,000	237,735,000,000
Long term loan VND	*292,417,136,083*	*60,353,000,000*	*11,186,400,000.00*	*243,250,536,083*
- Shareholder - Nguyen Phuong Vy	63,464,336,093	-	-	63,464,336,093
- Shareholder - Pham Huong Giang	78,649,999,990	-	-	78,649,999,990
- Danang City Development Investment	150,302,800,000	60,353,000,000	11,186,400,000	101,136,200,000
Totals	**695,545,602,343**	**532,119,650,064**	**514,406,465,426**	**677,832,417,705**

** Short-term loan from DANHSON-BG LTD under contract No. 01/2022/DNP-DS dated 01/05/2022 with a term of 5 years from 01/05/2022 to 01/05/2027 to purchase machinery and equipment for the project "Pharmaceutical manufacturing plant and high-tech research and development center" with a credit limit of EUR 7,500,000 at an annual interest rate of 3.5%.*

As of the reporting date, the loan has been classified as a current liability because the remaining period to maturity is less than 12 months. The Company is in the process of assessing and implementing appropriate measures to ensure that all obligations related to the loan will be fulfilled in full upon maturity.

13. Trade payables

	At as 30/06/2026	At as 01/01/2026
a. Short-term trade payables		
- Danhson BG Ltd	92,765,370,500	72,145,826,400
- Toan Phuc Chemical & Pharmaceutical Co., Ltd.	9,383,079,930	6,481,797,000
- METECNO (Vietnam) Co., Ltd.	6,253,263,542	9,182,517,856
- Bach Khoa Refrigeration & Electrical Engineering Co., Ltd	3,744,694,068	27,729,514,986
- Other short-term payables	71,394,254,989	84,339,832,077
Totals	**183,540,663,029**	**199,879,488,319**
b. Long-term trade payables		
- Danhson BG Ltd	217,784,327,145	328,383,111,022
Totals	**217,784,327,145**	**328,383,111,022**

14. Tax and statutory obligations:

a. Must pay

	At as 01/01/2026	Payable in the year	Paid in the year	Deducted amount	At as 30/06/2026
- Value added tax		12,187,438,547		12,187,438,547	-
- Value-Added Tax		2,973,776,970	2,973,776,970		-
- Special consumption tax					-
- Import and export tax		181,164,291	190,293,172		(9,128,881)
- Enterprise income tax	14,656,471,831	23,907,492,017	18,381,066,861		20,182,896,987
- Personal income tax	1,951,494,859	11,519,854,477	9,528,221,986		3,943,127,350
- Tax on use of nature					-
- Land & housing tax,		3,055,801,749	1,527,900,875		1,527,900,874
- Environment protection		2,469,433,815	2,469,433,815		-
- Fee, charges and other					-
Totals	**16,607,966,690**	**56,294,961,866**	**35,070,693,679**	**12,187,438,547**	**25,644,796,330**

b. Receivables

	At as 01/01/2026	Receivables for the period	Receipts for the period	Amount deducted	At as 30/06/2026
- Deductible VAT	24,036,861,319	16,068,611,412	9,947,620,348	12,187,438,547	17,970,413,836
Totals	**24,036,861,319**	**16,068,611,412**	**9,947,620,348**	**12,187,438,547**	**17,970,413,836**

15. Accrued expenses

	At as 30/06/2026	At as 01/01/2026
-GMP appraisal consultance expense, drug registration and software copyright rental must be paid to Danhson BG Ltd.		126,268,287
- Accrued selling expenses	26,021,365,620	33,350,399,971
- Other accruals		1,059,116,251
Totals	**26,021,365,620**	**34,535,784,509**

16. Other payables

	At as 30/06/2026	At as 01/01/2026
- Loan interest payable to Pham Huong Giang (Loan interest for the High-Tech Project)	8,866,355,655	32,281,883,973
Danhson - BG Ltd	*3,918,023,852*	*28,725,497,227*
Phạm Hương Giang	*1,903,659,969*	*2,835,359,387*
Nguyễn Phương Vy	*2,912,496,264*	*719,884,236*
Others		*1,143,123*
- Trade Union fees	63,050,900	56,556,486
- Dividends and profits paid		-
- Other short-term payables(*)	2,754,231,339	280,767,798
Totals	**11,683,637,894**	**32,619,208,257**

17. Capital

a. Reconciliation of changes in equity

	Contributed legal capital VND	*Share premium VND*	*Treasury shares VND*	*Investment and development funds VND*	*Retained earnings VND*	*Totals VND*
As at 01/01/2025	**209,380,000,000**	**181,169,607,584**	**-**	**304,136,126,279**	**70,241,659,293**	**764,927,393,156**
Profit in last year	-	-	-	-	85,749,552,728	85,749,552,728
Distributed bonus and welfare fund	-	-	-	-	-	-
Distributed Investment and development fund	-	-	-	69,998,059,293	(69,998,059,293)	-
Dividends distribution	-	-	-	-	-	-
Buy back and cancel treasury shares	-	-	-	-	-	-
At as 31/12/2025	**209,380,000,000**	**181,169,607,584**	**-**	**374,134,185,572**	**85,993,152,728**	**850,676,945,884**
Profit in last year	-	-	-	-	70,689,574,828	70,689,574,828
Distributed bonus and welfare fund	-	-	-	-	-	-
Distributed Investment and development fund	-	-	-	85,993,152,728	(85,993,152,728)	-
Dividends distribution	-	-	-	-	-	-
Buy back and cancel treasury shares	-	-	-	-	-	-
As at 30/06/2026	**209,380,000,000**	**181,169,607,584**	**-**	**460,127,338,300**	**70,689,574,828**	**921,366,520,712**

b. Corporate funds

	At as 30/06/2026	At as 01/01/2026
- Development Investment Fund	460,127,338,300	374,134,185,572

VI. ADDITIONAL INFORMATION FOR ITEMS PRESENTED IN INCOME STATEMENT

Unit of measurement: VND

01. Revenue from sale of goods and of services

	QII.2026	QII.2025
Revenue from the sale of goods and finished products.	193,288,061,671	155,342,413,490
Service revenue	54,545,457	54,545,457
Totals	**193,342,607,128**	**155,396,958,947**

02. Deductions

Including:

	QII.2026	QII.2025
- Trade discount	-	-
- Sales discount	-	875,314
- Sales returns	1,947,656,505	357,139,103
Totals	**1,947,656,505**	**358,014,417**

03. Cost of goods sold

	QII.2026	QII.2025
- Cost of goods sold	90,525,116,479	69,354,705,264
- Cost of services provided		
- Provision for inventories	-	965,600,012
- Credits reduce cost of goods sold		-
Totals	**90,525,116,479**	**70,320,305,276**

04. Financial income

	QII.2026	QII.2025
- Interest income	208,031,605	131,886,301
- Realized foreign exchange gain	1,490,297,072	3,083,753,702
Totals	**1,698,328,677**	**3,215,640,003**

05. Financial expenses

	QII.2026	QII.2025
- Interest loan	5,068,983,773	2,057,730,127
- Unrealized exchange loss	135,138,251	22,270,520,469
- Realized exchange loss	383,451,685	-
Totals	**5,587,573,709**	**24,328,250,596**

06. Other income

	QII.2026	QII.2025
- Liquidation and sale of fixed assets	235,721,888	-
- Other incomes	83,500,000	36,300,752
Totals	**319,221,888**	**36,300,752**

07. Other expensive

	QII.2026	QII.2025
- Administrative penalties	10,000,000	12,000,000
- Other expenses	143,549,816	47,197,781
Totals	**153,549,816**	**59,197,781**

08. Selling expenses

	QII.2026	QII.2025
- Employee expenses	3,122,700,598	5,901,608,890
- Raw materials and packaging costs	7,023,945	5,481,637
- Tools and supplies expenses	21,065,849	14,589,948
- Depreciation expenses of fixed assets	265,072,285	230,364,567
- Warranty and bid guarantee expenses	185,463,681	165,179,823
- Transportation and loading/unloading expenses	1,073,852,176	832,349,690
- Advertising, trade fair introduction, and customer conference expenses	190,295,319	183,253,138
- Other monetary expenses	11,288,533,072	17,591,436,624
- Other expenses	217,249,832	248,579,610
Totals	**16,371,256,757**	**25,172,843,927**

09. Adminitration expenses

	QII.2026	QII.2025
- Employee expenses	17,468,036,605	12,254,685,024
- Raw materials and packaging costs	587,288,706	2,052,336,805
- Tools and supplies expenses	56,088,043	74,729,662
- Depreciation expenses of fixed assets	3,162,451,020	1,517,764,820
- Taxes, Fees and Charges	2,157,217,439	111,964,707
- Provision cost	-	-
- External services cost	3,862,930,465	3,261,771,091
- Other Cash Expenses	7,570,789,387	8,276,207,900
Totals	**34,864,801,665**	**27,549,460,009**

10. **Deferred income tax (expenses) credit**

	QII.2026	QII.2025
	(1,488,277,305)	**4,225,027,793**

VII.RELATED PARTIES

List of related parties	**Relationship**
1. Danhson VN Company Limited	Holding Company
2. Vietnam Pharmaceutical Corporation - JSC	Major shareholder
3. Danhson - BG Ltd	Common key management personnel
4. Ms. Nguyen Phuong Vy	Related party of the parent company
5. Ms. Pham Huong Giang	Related party of the parent company
6. Danhson Trading VN Co., Ltd	Common key management personnel
7. Board of Directors and management	Key management personnel
8. Vetprom AD	Common key management personnel

VIII. COMPARATIVE INFORMATION

As at December 31st 2025, the Company still had a balance recorded under the item "Funding sources, other funds."

Pursuant to Circular No. 99/2025/TT-BTC dated October 27 2025, the Board of Directors decided to reclassify this balance to the item "Other payables" for the financial reporting period as at 31 March 2026.

Item	Code	As at 01/01/2026	As at 31/12/2025	Difference
		Balance carried forward	*Previously reported*	
Other short-term payables	320	32,761,761,777	32,619,208,257	142,553,520
Funding sources	431	-	142,553,520	(142,553,520)

Nguyen Thi Thu Hang	**Tran Tien Dung**	**Le Thang Binh**
Preparer	**Chief Accountant**	**General Director**

Da Nang, July 18th 2026